Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. - Wikidata - wikimedia - TriplyDB

Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis.

Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis.

http://www.wikidata.org/entity/Q37206612

about

Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges Glucocorticoid-induced osteoporosis Impact of inflammation on the osteoblast in rheumatic diseases Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort.Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis.Serum Sclerostin Levels in Patients with Ankylosing Spondylitis and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Novel therapeutic targets in myeloma bone disease.Quantitative analysis of bone and soft tissue by micro-computed tomography: applications to ex vivo and in vivo studies Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis.Quantifying not only bone loss, but also soft tissue swelling, in a murine inflammatory arthritis model using micro-computed tomography New horizons in treatment of osteoporosis.Synovium-Derived MicroRNAs Regulate Bone Pathways in Rheumatoid Arthritis.Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts.Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study.Sclerostin: More than a bone formation brake.The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study.Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis.Emerging treatment approaches for myeloma-related bone disease.The role of stromal cells in inflammatory bone loss.Inflammatory diseases and bone fragility.Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial.Sclerostin expression and functions beyond the osteocyte.Application of anti-Sclerostin therapy in non-osteoporosis disease models.Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction.Early sclerostin expression explains bone formation inhibition before arthritis onset in the rat adjuvant-induced arthritis model.Bone erosions in rheumatoid arthritis: recent developments in pathogenesis and therapeutic implications

P2860

Q26744599-ADF53003-BA83-40D7-97FC-9D1B7834B53C Q26778272-1EFBEC0B-5B73-4633-813D-BD03A4277879 Q26829246-B8D162D6-025E-4216-B60A-48C5DA6D53F1 Q30990351-E7F3E7B2-0BC1-4CF2-9235-2A1125611ADF Q31038073-9A06B8DE-5AFE-4218-A40E-CF470EB26B6A Q33592037-3C1B7C44-4802-4659-9A98-439D6C03BFD3 Q33695718-F8510943-61D7-4F2C-9194-8810053AF928 Q34025065-EB4B962F-41BB-4A7C-9F5E-B7F302535CD1 Q34074442-F1646C18-21E9-46B3-BD6A-D36C252CBB40 Q34537434-C4DD52FF-1FC5-40E3-9B28-6A71EC345B8E Q35086184-31C6E5D3-6A4E-4E18-87A1-04E10B46B14B Q37630995-2C369285-751B-4A9C-9189-15E1A940A9DF Q38441150-C4CBC4FD-9C21-4B53-9D91-41721B80CB00 Q38593977-4B7CBB81-D69D-4E4E-8BE4-FB5B42487EEE Q38652133-2A84E4E3-68E4-4FDA-B6BF-C60F75F776D0 Q38810985-5D5A654B-A53C-4870-9E1C-D6B284CFB8AD Q38831693-71ABC6CC-3E90-4165-A3A8-1FC121945786 Q38998373-9031B3A1-2BAF-492B-B69A-6D5D6DBAA8A2 Q39090721-64A404D6-F87E-4078-A836-CCDD66D2D7FB Q39248512-AC3200EC-9BA1-42B1-97F3-D2A8A5A07AC4 Q47975714-724E7727-1F7F-4385-A651-AA50F6EA4C96 Q50979781-50CDBC62-F542-44AF-9935-32E30C2826C2 Q51303428-4B0BE94A-456D-42B2-9740-1CF3AB3F601F Q51363424-E728E2A6-36A0-47CA-8B1E-FE42DB7A16D1 Q55025334-0A414B29-4534-4CD4-A85D-1A360DB1069D Q55250907-0F51BF91-F21B-4249-8859-92BBBD7DCF65 Q58774487-C4B24671-FC73-4D31-AF18-8C815F253412

P2860

Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis.

http://www.wikidata.org/entity/Q37206612

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis.

@en

Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis.

@nl

type

label

Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis.

@en

Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis.

@nl

prefLabel

Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis.

@en

Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis.

@nl

P1433

Q37206612-2D6032B4-0E07-43D4-A437-17646943F502

P1476

Q37206612-767C3FA3-4EC0-43AD-8F3C-435152176101

P2093

Q37206612-079A6FED-0B42-4F49-A3A3-A416D1B8E53F

Q37206612-12ECC89F-A270-4BDC-8248-9A5A0BBA2CB6

Q37206612-26A87BEA-2C98-4F5F-B368-8D6063B48DF9

Q37206612-60DACC1D-EDE9-4487-9D78-CB95F2E03A7D

Q37206612-96AE1B88-2590-448D-81D0-3B27655344BA

Q37206612-C4F4FCEE-3E52-4B64-8F1B-402989401A37

Q37206612-D4FE2212-38BC-4727-BE40-6CA8F5FA2B8F

Q37206612-EEAE3C3C-138D-4752-86FA-F8578E87A2C4

P2860

Q37206612-01B2324C-0446-48F5-9722-6084B71AE784

Q37206612-040968E0-1B34-4063-9C3F-92A1C2C7096D

Q37206612-11438100-7105-4937-ADD5-7D926032AA91

Q37206612-40C0585B-3F94-4A7E-96BA-4BCA77EE73B3

Q37206612-5DDD4927-7CBD-4FB4-9376-0BEAF7E3FE9D

Q37206612-7ED3A3E4-8FF1-4286-861C-F544995FDE12

Q37206612-946C235B-D982-4800-AF74-B9D7CF9F5AF4

Q37206612-B2BEA820-C7F1-43E3-BB02-636536397F58

Q37206612-C2B28C6D-8C19-4FB4-BE8C-5B92C551E953

Q37206612-C8E9BE73-7160-4D1F-9FB3-3E852D03FAB7

P304

Q37206612-3C9C39A6-F8F3-41EC-8B45-463555BA3086

P31

Q37206612-56C724A6-C1CD-4CA1-81BF-91822B168198

P356

Q37206612-FB7A75A7-A28D-4AC4-B661-E8D1B4413B92

P407

Q37206612-F499ECED-52D8-45B9-B193-2948D969B9C8

P433

Q37206612-9C98DAA8-3709-49AE-8D2A-09793DFD19DD

P478

Q37206612-774186A9-D831-437C-981A-B822301639CC

P50

Q37206612-28ECC5B3-E939-409B-B093-D7BB33EFFE2F

P577

Q37206612-AAC4900F-3AE5-46C9-9228-907FB9BEAF18

P5875

Q37206612-68E18A51-E7FE-468C-A9E2-9907ED54F29F

P698

Q37206612-68C1470B-597C-46F8-974A-18DFA53468B4

P932

Q37206612-C0D3AEEE-54A3-4AA9-84D4-E429B7819F6E

P356

ANNRHEUMDIS-2013-203345

P1433

Annals of the Rheumatic Diseases

P1476

Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis.

@en

P2093

Aline Bozec

http://www.w3.org/2001/XMLSchema#string

Denise Dwyer

http://www.w3.org/2001/XMLSchema#string

Hua-Zhu Ke

http://www.w3.org/2001/XMLSchema#string

Kay Schwabe

http://www.w3.org/2001/XMLSchema#string

Marina Stolina

http://www.w3.org/2001/XMLSchema#string

Michael Stock

http://www.w3.org/2001/XMLSchema#string

Wolfgang Baum

http://www.w3.org/2001/XMLSchema#string

Xiao-Xiang Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

The pathogenesis of rheumatoid arthritis

Osteoporosis and arthritis.

Disease activity and severity in early inflammatory arthritis predict hand cortical bone loss

From bone biology to clinical outcome: state of the art and future perspectives.

Targeting sclerostin as potential treatment of osteoporosis.

Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis.

P304

1732-1736

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2013-203345

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236692730

http://www.w3.org/2001/XMLSchema#string

P698

23666928

http://www.w3.org/2001/XMLSchema#string

P932

3786639

http://www.w3.org/2001/XMLSchema#string